drugset / Trial / NCT01319929

A Study of LY2828360 in Patients With Osteoarthritic Knee Pain

NCT01319929 ↗

Phase 2 Completed 39 enrolled Eli Lilly and Company
RandomizedCrossoverDouble-blindOther

Summary

To investigate the safety, efficacy and pharmacokinetics of single daily oral dose of LY2828360 in male and female subjects with osteoarthritic knee pain

Timeline

Start
2011-03
Primary completion
2011-09
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Subject LY2828360 Small molecule 80 mg Oral

Indications